【摘要】 目的:观察门冬氨酸鸟氨酸联合前列地尔治疗重症肝炎的疗效和安全性。方法:将60例重症肝炎患者随机均分为对照组和试验组。对照组患者给予常规护肝治疗;试验组患者在给予常规护肝治疗的同时,给予门冬氨酸鸟氨酸10 g加入木糖醇注射液250 ml中静脉滴注,qd,并给予前列地尔10μg加入5%葡萄糖注射液100 ml中静脉滴注,qd。两组患者疗程均为4周。观察两组患者的临床疗效及肝功能指标的变化,并观察不良反应情况。结果:试验组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.01);试验组患者各项肝功能指标改善均显著优于对照组,两组比较差异均有统计学意义(P<0.01);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:门冬氨酸鸟氨酸联合前列地尔治疗重症肝炎具有较好的疗效,且不增加不良反应发生的风险。更多还原

【Abstract】 OBJECTIVE:To observe the therapeutic efficacy and safety of ornithine aspartate combined with alprostadil in the treatment of severe hepatitis. METHODS:60 cases of severe hepatitis were randomly divided into control group and trial group.Control group received conventional liver-protecting treatment. Trial group additionally received ornithine aspartate 10 g added into Xylosic alcohol injection 250 ml intravenously,qd,and alprostadil 10 μg added into 5% Glucose injection 100 ml intravenously,qd,on the basis of conventional liver-protecting treatment. Treatment course of 2 groups lasted for 4 weeks. Clinical efficacy and liver function index were observed in 2 groups,and the occurrence of ADR was observed. RESULTS:Total effective rate of trial group was significantly higher than that of control group;there was statistical significance(P<0.01);the improvement of liver function index in trial group was significantly better than in control group;there was statistical significance(P<0.01);there was no statistical significance(P>0.05). CONCLUSIONS:Ornithine aspartate combined with alprostadil in effective and safe for severe hepatitis.更多还原